Milestone Pharmaceuticals NMPA approval triggers $2 million milestone payment
Milestone Pharmaceuticals (NASDAQ:MIST) says NMPA approval triggers a $2 million milestone payment to the company.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Milestone Pharmaceuticals gets NMPA approval for Etripamil nasal spray in China
Milestone Pharmaceuticals said China’s NMPA approved its etripamil nasal spray for PSVT, the first Etripamil regulatory approval outside the United States.